These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Transporter and neurological disease]. Kawakami H Rinsho Shinkeigaku; 1999 Jan; 39(1):7-8. PubMed ID: 10377785 [TBL] [Abstract][Full Text] [Related]
9. Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions. Bjerggaard C; Fog JU; Hastrup H; Madsen K; Loland CJ; Javitch JA; Gether U J Neurosci; 2004 Aug; 24(31):7024-36. PubMed ID: 15295038 [TBL] [Abstract][Full Text] [Related]
10. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Uhl GR Ann Neurol; 1998 May; 43(5):555-60. PubMed ID: 9585349 [No Abstract] [Full Text] [Related]
11. Probing structure of neurotransmitter transporters by substituted-cysteine accessibility method. Javitch JA Methods Enzymol; 1998; 296():331-46. PubMed ID: 9779459 [No Abstract] [Full Text] [Related]
17. Neurotransmitter transporters (plus): a promising new gene family. Uhl GR Trends Neurosci; 1992 Jul; 15(7):265-8. PubMed ID: 1381123 [TBL] [Abstract][Full Text] [Related]
18. Recent biochemical studies of the dopamine transporter--a CNS drug target. Kuhar MJ Life Sci; 1998; 62(17-18):1573-5. PubMed ID: 9585138 [TBL] [Abstract][Full Text] [Related]
19. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. Richelson E J Clin Psychiatry; 2003; 64 Suppl 13():5-12. PubMed ID: 14552650 [TBL] [Abstract][Full Text] [Related]